Cargando…
High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis
Corticosteroids are largely recommended in patients with severe COVID-19. However, evidence to support high-dose methylprednisolone (MP) pulses is not as robust as that demonstrated for low-dose dexamethasone (DXM) in the RECOVERY trial. This is a retrospective cohort study on severe, non-critically...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509662/ https://www.ncbi.nlm.nih.gov/pubmed/34640481 http://dx.doi.org/10.3390/jcm10194465 |
_version_ | 1784582396395388928 |
---|---|
author | Mora-Luján, José María Tuells, Manel Montero, Abelardo Formiga, Francesc Homs, Narcís A. Albà-Albalate, Joan Corbella, Xavier Rubio-Rivas, Manuel |
author_facet | Mora-Luján, José María Tuells, Manel Montero, Abelardo Formiga, Francesc Homs, Narcís A. Albà-Albalate, Joan Corbella, Xavier Rubio-Rivas, Manuel |
author_sort | Mora-Luján, José María |
collection | PubMed |
description | Corticosteroids are largely recommended in patients with severe COVID-19. However, evidence to support high-dose methylprednisolone (MP) pulses is not as robust as that demonstrated for low-dose dexamethasone (DXM) in the RECOVERY trial. This is a retrospective cohort study on severe, non-critically ill patients with COVID-19, comparing 3-day MP pulses ≥ 100 mg/day vs. DXM 6 mg/day for 10 days. The primary outcome was in-hospital mortality, and the secondary outcomes were need of intensive care unit (ICU) admission or invasive mechanical ventilation (IMV). Propensity-score matching (PSM) analysis was applied. From March 2020 to April 2021, a total of 2,284 patients were admitted to our hospital due to severe, non-critically ill COVID-19, and of these, 189 (8.3%) were treated with MP, and 493 (21.6%) with DXM. The results showed that patients receiving MP showed higher in-hospital mortality (31.2% vs. 17.8%, p < 0.001), need of ICU admission (29.1% vs. 20.5%, p = 0.017), need of IMV (25.9% vs. 13.8, p < 0.001), and median hospital length of stay (14 days vs. 11 days, p < 0.001). Our results suggest that treatment with low-dose DXM for 10 days is superior to 3 days of high-dose MP pulses in preventing in-hospital mortality and need for ICU admission or IMV in severe, non-critically ill patients with COVID-19. |
format | Online Article Text |
id | pubmed-8509662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85096622021-10-13 High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis Mora-Luján, José María Tuells, Manel Montero, Abelardo Formiga, Francesc Homs, Narcís A. Albà-Albalate, Joan Corbella, Xavier Rubio-Rivas, Manuel J Clin Med Article Corticosteroids are largely recommended in patients with severe COVID-19. However, evidence to support high-dose methylprednisolone (MP) pulses is not as robust as that demonstrated for low-dose dexamethasone (DXM) in the RECOVERY trial. This is a retrospective cohort study on severe, non-critically ill patients with COVID-19, comparing 3-day MP pulses ≥ 100 mg/day vs. DXM 6 mg/day for 10 days. The primary outcome was in-hospital mortality, and the secondary outcomes were need of intensive care unit (ICU) admission or invasive mechanical ventilation (IMV). Propensity-score matching (PSM) analysis was applied. From March 2020 to April 2021, a total of 2,284 patients were admitted to our hospital due to severe, non-critically ill COVID-19, and of these, 189 (8.3%) were treated with MP, and 493 (21.6%) with DXM. The results showed that patients receiving MP showed higher in-hospital mortality (31.2% vs. 17.8%, p < 0.001), need of ICU admission (29.1% vs. 20.5%, p = 0.017), need of IMV (25.9% vs. 13.8, p < 0.001), and median hospital length of stay (14 days vs. 11 days, p < 0.001). Our results suggest that treatment with low-dose DXM for 10 days is superior to 3 days of high-dose MP pulses in preventing in-hospital mortality and need for ICU admission or IMV in severe, non-critically ill patients with COVID-19. MDPI 2021-09-28 /pmc/articles/PMC8509662/ /pubmed/34640481 http://dx.doi.org/10.3390/jcm10194465 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mora-Luján, José María Tuells, Manel Montero, Abelardo Formiga, Francesc Homs, Narcís A. Albà-Albalate, Joan Corbella, Xavier Rubio-Rivas, Manuel High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis |
title | High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis |
title_full | High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis |
title_fullStr | High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis |
title_full_unstemmed | High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis |
title_short | High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis |
title_sort | high-dose methylprednisolone pulses for 3 days vs. low-dose dexamethasone for 10 days in severe, non-critical covid-19: a retrospective propensity score matched analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509662/ https://www.ncbi.nlm.nih.gov/pubmed/34640481 http://dx.doi.org/10.3390/jcm10194465 |
work_keys_str_mv | AT moralujanjosemaria highdosemethylprednisolonepulsesfor3daysvslowdosedexamethasonefor10daysinseverenoncriticalcovid19aretrospectivepropensityscorematchedanalysis AT tuellsmanel highdosemethylprednisolonepulsesfor3daysvslowdosedexamethasonefor10daysinseverenoncriticalcovid19aretrospectivepropensityscorematchedanalysis AT monteroabelardo highdosemethylprednisolonepulsesfor3daysvslowdosedexamethasonefor10daysinseverenoncriticalcovid19aretrospectivepropensityscorematchedanalysis AT formigafrancesc highdosemethylprednisolonepulsesfor3daysvslowdosedexamethasonefor10daysinseverenoncriticalcovid19aretrospectivepropensityscorematchedanalysis AT homsnarcisa highdosemethylprednisolonepulsesfor3daysvslowdosedexamethasonefor10daysinseverenoncriticalcovid19aretrospectivepropensityscorematchedanalysis AT albaalbalatejoan highdosemethylprednisolonepulsesfor3daysvslowdosedexamethasonefor10daysinseverenoncriticalcovid19aretrospectivepropensityscorematchedanalysis AT corbellaxavier highdosemethylprednisolonepulsesfor3daysvslowdosedexamethasonefor10daysinseverenoncriticalcovid19aretrospectivepropensityscorematchedanalysis AT rubiorivasmanuel highdosemethylprednisolonepulsesfor3daysvslowdosedexamethasonefor10daysinseverenoncriticalcovid19aretrospectivepropensityscorematchedanalysis |